EP2016952 - A method of treating a malignancy in a subject and a pharmaceutical composition for use in same [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 31.10.2014 Database last updated on 31.08.2024 | Most recent event Tooltip | 08.07.2016 | Lapse of the patent in a contracting state New state(s): TR | published on 10.08.2016 [2016/32] | Applicant(s) | For all designated states Viralytics Limited Suite 305 66 Hunter Street Sydney NSW 2000 / AU | [2013/38] |
Former [2009/04] | For all designated states Viralytics Limited 8/33 Ryde Road Pymble, NSW 2113 / AU | Inventor(s) | 01 /
Shafren, Darren 14 High Street The Hill Newcastle 2300, NSW / AU | [2013/52] |
Former [2009/30] | 01 /
Shafren, Darren 14 High Street The Hill Newcastle 2300, NSW / AU | Representative(s) | Wakerley, Helen Rachael Reddie & Grose LLP The White Chapel Building 10 Whitechapel High Street London E1 8QS / GB | [N/P] |
Former [2013/52] | Wakerley, Helen Rachael Reddie & Grose LLP 16 Theobalds Road London WC1X 8PL / GB | ||
Former [2009/04] | Wakerley, Helen Rachael Reddie & Grose 16 Theobalds Road London WC1X 8PL / GB | Application number, filing date | 08018165.4 | 27.11.2000 | [2009/04] | Priority number, date | AU1999PQ04256 | 25.11.1999 Original published format: AU PQ425699 | [2009/04] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | EP2016952 | Date: | 21.01.2009 | Language: | EN | [2009/04] | Type: | A3 Search report | No.: | EP2016952 | Date: | 19.05.2010 | [2010/20] | Type: | B1 Patent specification | No.: | EP2016952 | Date: | 25.12.2013 | Language: | EN | [2013/52] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 16.04.2010 | Classification | IPC: | A61K39/12, A61K39/125, A61K39/235, A61K39/245, A61K39/215, A61P35/00, A61P35/04 | [2009/04] | CPC: |
A61K35/768 (EP,US);
A61K9/0019 (US);
A61P35/00 (EP);
A61P35/04 (EP);
C12N7/00 (US);
C12Q1/025 (US);
G01N33/5011 (EP,US);
C12N2770/32332 (EP,US);
C12N2770/32333 (US);
C12N2770/32371 (US)
(-)
| Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2009/04] | Title | German: | Verfahren zur Behandlung von Malignomen in einem Patienten und pharmazeutische Zusammensetzung zur Verwendung dafür | [2009/04] | English: | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same | [2009/04] | French: | Procédé de traitement d'une tumeur chez un sujet et composition pharmaceutique l'utilisant | [2009/04] | Examination procedure | 13.11.2008 | Examination requested [2009/04] | 07.03.2011 | Amendment by applicant (claims and/or description) | 27.06.2011 | Despatch of a communication from the examining division (Time limit: M06) | 14.02.2012 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 13.04.2012 | Reply to a communication from the examining division | 09.07.2013 | Communication of intention to grant the patent | 07.11.2013 | Fee for grant paid | 07.11.2013 | Fee for publishing/printing paid | Parent application(s) Tooltip | EP00979268.0 / EP1235590 | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20000979268) is 07.10.2005 | Opposition(s) | 26.09.2014 | No opposition filed within time limit [2014/49] | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 13.04.2012 | Request for further processing filed | 13.04.2012 | Full payment received (date of receipt of payment) Request granted | 27.04.2012 | Decision despatched | The application is deemed to be withdrawn due to failure to indicate the wish to proceed further with the application | 24.02.2011 | Request for further processing filed | 24.02.2011 | Full payment received (date of receipt of payment) Request granted | 14.03.2011 | Decision despatched | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 24.02.2011 | Request for further processing filed | 24.02.2011 | Full payment received (date of receipt of payment) Request granted | 14.03.2011 | Decision despatched | Fees paid | Renewal fee | 13.11.2008 | Renewal fee patent year 03 | 13.11.2008 | Renewal fee patent year 04 | 13.11.2008 | Renewal fee patent year 05 | 13.11.2008 | Renewal fee patent year 06 | 13.11.2008 | Renewal fee patent year 07 | 13.11.2008 | Renewal fee patent year 08 | 13.11.2008 | Renewal fee patent year 09 | 12.11.2009 | Renewal fee patent year 10 | 12.11.2010 | Renewal fee patent year 11 | 14.11.2011 | Renewal fee patent year 12 | 13.11.2012 | Renewal fee patent year 13 | 18.11.2013 | Renewal fee patent year 14 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AT | 25.12.2013 | BE | 25.12.2013 | CY | 25.12.2013 | DK | 25.12.2013 | FI | 25.12.2013 | NL | 25.12.2013 | SE | 25.12.2013 | TR | 25.12.2013 | GR | 26.03.2014 | PT | 28.04.2014 | [2016/32] |
Former [2016/28] | AT | 25.12.2013 | |
BE | 25.12.2013 | ||
CY | 25.12.2013 | ||
DK | 25.12.2013 | ||
FI | 25.12.2013 | ||
NL | 25.12.2013 | ||
SE | 25.12.2013 | ||
GR | 26.03.2014 | ||
PT | 28.04.2014 | ||
Former [2014/48] | AT | 25.12.2013 | |
BE | 25.12.2013 | ||
CY | 25.12.2013 | ||
DK | 25.12.2013 | ||
FI | 25.12.2013 | ||
NL | 25.12.2013 | ||
SE | 25.12.2013 | ||
PT | 28.04.2014 | ||
Former [2014/39] | AT | 25.12.2013 | |
BE | 25.12.2013 | ||
CY | 25.12.2013 | ||
FI | 25.12.2013 | ||
NL | 25.12.2013 | ||
SE | 25.12.2013 | ||
PT | 28.04.2014 | ||
Former [2014/37] | AT | 25.12.2013 | |
BE | 25.12.2013 | ||
CY | 25.12.2013 | ||
FI | 25.12.2013 | ||
SE | 25.12.2013 | ||
PT | 28.04.2014 | ||
Former [2014/34] | BE | 25.12.2013 | |
FI | 25.12.2013 | ||
SE | 25.12.2013 | ||
Former [2014/22] | FI | 25.12.2013 | |
SE | 25.12.2013 | Documents cited: | Search | [A]WO9918799 (PRO VIRUS INC [US], et al) [A] 1-15 * the whole document *; | [XI] - POND A R ET AL, "ONCOLYTIC EFFECT OF POLIOMYELITIS VIRUS ON HUMAN EPIDERMOID CARCINOMA (HELA TUMOR) HETEROLOGOUSLY TRANSPLANTED TO GUINEA PIGS", AMERICAN JOURNAL OF PATHOLOGY, AMERICAN SOCIETY FOR INVESTIGATIVE PATHOLOGY, US, (19640801), vol. 45, ISSN 0002-9440, pages 233 - 249, XP009131699 [X] 1,4-6,10,12,14,15 * the whole document * [I] 3,7-9,13 | [Y] - NEMUNAITIS J, "ONCOLYTIC VIRUSES", INVESTIGATIONAL NEW DRUGS, MARTINUS NIJHOFF PUBLISHERS, BOSTON, US LNKD- DOI:10.1023/A:1006334404767, (19990101), vol. 17, no. 4, ISSN 0167-6997, pages 375 - 386, XP008022175 [Y] 1-15 * abstract * * page 376, column l, paragraph 2 - paragraph 3 * DOI: http://dx.doi.org/10.1023/A:1006334404767 | [Y] - SHAFREN D R, "Viral cell entry induced by cross-linked decay-accelerating factor", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, (19980101), vol. 72, no. 11, ISSN 0022-538X, pages 9407 - 9412, XP002904990 [Y] 1-15 * page 9408, column r, paragraph 2 * * figure 3B * | [XPI] - GROMEIER M ET AL, "Intergeneric poliovirus recombinants for the treatment of malignant glioma.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 6 JUN 2000 LNKD- PUBMED:10841575, (20000606), vol. 97, no. 12, ISSN 0027-8424, pages 6803 - 6808, XP002965080 [XP] 1,4-6,8,10,12,14,15 * the whole document * [I] 3,7,9,13 DOI: http://dx.doi.org/10.1073/pnas.97.12.6803 | [A] - SUSKIND R G ET AL, "Viral agents oncolytic for human tumors in heterologous host; oncolytic effect of Coxsackie B viruses.", PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE. SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE (NEW YORK, N.Y.) FEB 1957 LNKD- PUBMED:13408245, (195702), vol. 94, no. 2, ISSN 0037-9727, pages 309 - 318, XP009131831 [A] 1-15 * the whole document * | [A] - TAYLOR M W ET AL, "Viruses as an aid to cancer therapy: regression of solid and ascites tumors in rodents after treatment with bovine enterovirus", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. (PNAS), NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US LNKD- DOI:10.1073/PNAS.68.4.836, (19710401), vol. 68, no. 4, ISSN 0027-8424, pages 836 - 840, XP002526526 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1073/pnas.68.4.836 | [A] - SEDMAK G V ET AL, "Oncolytic effect of bovine enterovirus on mouse and human tumours.", NATURE: NEW BIOLOGY 5 JUL 1972 LNKD- PUBMED:18663833, (19720705), vol. 238, no. 79, ISSN 0090-0028, pages 7 - 9, XP009131829 [A] 1-15 * the whole document * | [A] - MILLER B E ET AL, "Intercellular adhesion molecule-1 (ICAM-1) expression by human melanoma cells: association with leukocyte aggregation and metastatic potential", CLINICAL AND EXPERIMENTAL METASTASIS, SPRINGER NETHERLANDS, NL, (19900101), vol. 8, ISSN 0262-0898, XP002984008 [A] 1-15 * the whole document * | [L] - MAIER MICHAEL K ET AL, "The adhesion receptor CD155 determines the magnitude of humoral immune responses against orally ingested antigens.", EUROPEAN JOURNAL OF IMMUNOLOGY AUG 2007 LNKD- PUBMED:17621371, (200708), vol. 37, no. 8, ISSN 0014-2980, pages 2214 - 2225, XP009131815 [L] 1-15 * the whole document * DOI: http://dx.doi.org/10.1002/eji.200737072 | by applicant | - SICKLES G.M., PROC. SOC. EXP. BIOL. MED., vol. 102, page 742 | - SHAFREN D. ET AL., J. VIROL, (1997), vol. 71, page 4736 | - HUGHES ET AL., J. GEN VIROL., (1989), vol. 70, page 2943 | - SCHMIDT, N.J. ET AL., PROC. SOC. EXP. BIOL. MED., (1961), vol. 107, page 63 | - KAGESHITA T ET AL., "Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma", CANCER RES., (19931015), vol. 53, no. 20, pages 4927 - 32 | - KRAUS A; MASAT L; JOLMSON JP, "Analysis of the expression of intercellular adhesion molecule-1 and MUC18 on benign and malignant melanocytic lesions using monoclonal antibodies directed against distinct epitopes and recognising denatured, non-glycosylated antigen", MELANOMA RES., (19970807), vol. 2, pages 575 - 81 | - MORANDINI R ET AL., "Modulation of ICAM-1 expression by alpha-MSH in human melanoma cells and melanoxytes", J CELL PHYSIOL., (199806), vol. 175, no. 3, pages 276 - 82 | - STAUNTON DE ET AL., "A cell adhesion molecule, ICAM-1 is the major surface receptor for rhinoviruses", CELL, (1989), vol. 56, doi:doi:10.1016/0092-8674(89)90689-2, pages 849 - 853, XP023884492 DOI: http://dx.doi.org/10.1016/0092-8674(89)90689-2 | - CHEUNG NK ET AL., "Decay-acceleratingfactor protects human tumor cells from complement-mediated cytotoxicity in vitro", J CLIN INVEST., (199804), vol. 81, no. 4, doi:doi:10.1172/JCI113426, pages 1122 - 8, XP002984007 DOI: http://dx.doi.org/10.1172/JCI113426 | - NEMUNAITIS J, ONCOLYTIC VIRUSES. INVESTIGATIONAL NEW DRUGS, (1999), vol. 17, pages 375 - 386 | - ALEMANY R ET AL., "Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses", EXP CELL RES., (1999), vol. 252, pages 1 - 12 | - ANDREANSKY SS ET AL., "The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors", PROC NATL ACAD SCI USA, (1996), vol. 93, doi:doi:10.1073/pnas.93.21.11313, pages 11313 - 8, XP002207910 DOI: http://dx.doi.org/10.1073/pnas.93.21.11313 | - COFFEY MC ET AL., "Reovirus therapy of tumours with activated Ras pathway", SCIENCE, (1998), vol. 282, pages 1332 - 1334 | - STRONG JE ET AL., THE MOLECULAR BASIS OF VIRAL ONCOLYSIS: USURPATION OF THE RAS SIGNALLING PATHWAY BY REOVIRUS, (1998), vol. 17, no. 12, pages 3351 - 3362 | - RANDAZZO BP ET AL., "Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus l mutant", VIROLOGY, (1995), vol. 211, doi:doi:10.1006/viro.1995.1382, pages 94 - 101, XP000561228 DOI: http://dx.doi.org/10.1006/viro.1995.1382 | - SATYAMOORTHY K ET AL., "Adenovirus infection enhances killing of melanoma cells by a mitotoxin", CANCER RESEARCH, (1997), vol. 57, pages 1873 - 1876 | - HEMMI S ET AL., "The presence of human Coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures", HUMAN GENE THERAPY, (1998), vol. 9, pages 2363 - 2373, XP001068738 | - SHAFREN DR ET AL., "Coxsackievirus A2.1 binds to decay-accelerating factor but requires intercellular adhesion molecule I for cell entry", J VIROL., (199706), vol. 71, no. 6, pages 4736 - 43, XP002454005 | - BJØRGE L; JENSEN TS; MATRE R, "Characterisation of the complement- regulatory proteins decay-accelerating factnr (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line", CANCER IMMUNOL IMMUNOTHER, (1996), vol. 42, doi:doi:10.1007/s002620050269, pages 185 - 192, XP002984009 DOI: http://dx.doi.org/10.1007/s002620050269 | - NASU R ET AL., "Immunohistochemical analysis of intercellular adhesion molecule-1 expression in human gastric adenoma and adenocarcinoma", VIRCHOWS ARCH, (1997), vol. 430, pages 279 - 283 | - KOYAMA S; EBIHARA T; FUKAO K, "Expression of intercellular adhesion molecule 1 (ICAM-1) during the development of invasion and/or metastasis of gastric carcinoma", J. CANCER RES. CLIN. ONCOL., (1992), vol. 118, pages 609 - 614 | - ROKHLIN OW; COHEN MB, "Expression ofcellular adhesion molecules on human prostate tumor cell lines", PROSTATE, (199504), vol. 26, no. 4, pages 205 - 12 | - SGAGIAS MK ET AL., "Upregulation of DF3, in association with ICAM-1 and MHC class II by IFN- gamma in short-term human mammary carcinoma cell cultures", CANCER BIOTHER RADIOPHARM., (1996), vol. 11, pages 177 - 85 | - REGIDOR PA ET AL., "Expression of the cell adhesion molecules ICAM·1 and VCAM-1 in the cytosol of breast cancer tissue, benign breast tissue and corresponding sera", EUR J GYNAECOL ONCOL., (1998), vol. 19, pages 377 - 83 | - BACUSS SS ET AL., "Medullary carcinoma is associated with expression of intercellular adhesion molecule-1. Implication to its morphology and its clinical behaviour", AM J PATHOL., (199412), vol. 145, no. 6, pages 1337 - 1148 | - MALONEY DG; DONOVAN K; HAMBLIN TJ, "Antibody therapy for treatment of multiple myeloma", SEMINARS IN HEMATOLOGY, (1999), vol. 36, pages 30 - 33, XP000857401 | - FERNANDEZ-REAL JM ET AL., "Expression of ICAM-1 in distant metastatic thyroid carcinoma", J ENDOCRINOL INVEST., (199603), vol. 19, no. 3, pages 183 - 185 | - NATALIE PG ET AL., "Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule- expression in cutaneous malignant melanoma lesions", CANCER RES., (19970415), vol. 57, no. 8, pages 1554 - 60 | - REED LJ; MUENCH HA, "A simple method of estimatingfifty percent endpoints", AM J HYG., (1938), vol. 27, pages 493 - 497 | - BERENDT AR ET AL., "The binding site on ICAM-1 for plasmodium Jalciparum-infected erythrocytes overlaps, but is distinct from the LFA-1 binding site", CELL, (1992), vol. 68, pages 71 - 81 | - JOHNSON JP ET AL., "The melanoma progression-associated antigen P3.58 is identical to the intercellular adhesion molecule ICAM-1", IMMUNOLOGY, (1988), vol. 178, pages 275 - 284 | - MILLER BE; WELCH DR, "Intercellular adhesion molecule-1. (ICAM-1) expression by human melanoma cells; association with leukocyte aggregation and metastatic potential", CLIN. EXP. METASTASIS., (1990), vol. 8, page 80 | - LEA SM ET AL., "Determination of the affinity and kinetic constants for the interaction between the human virus echovirus 11 and its cellular receptor, CD55", J. BIOL. CHEM., (1998), vol. 273, pages 30443 - 60447 | - DAVIES CDL ET AL., "Comparison of extracellular matrix in human osteosarcomas and melanomas growing as xenogrqfts, multicellular spheroids and monolayer cultures", ANTICANCER RESEARCH., (1997), vol. 17, pages 4317 - 4326 |